BACKGROUND & AIMS: Hepatic steatosis is a common histologic finding in patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), although little is known about its natural history. We prospectively examined the natural history of steatosis in patients coinfected with HIV and HCV who attended an urban HIV clinic. METHODS: The study cohort consisted of 222 coinfected patients (87% black, 94% with HCV genotype 1 infection) who had at least 2 liver biopsies performed between 1993 and 2008. Biopsy specimens were scored by a single pathologist; samples were classified as having trivial (<5% of hepatocytes affected) or significant (>5%) levels of fat (steatosis). We characterized progression to significant levels of fat among patients whose first biopsy samples had no or trivial levels of fat, and regression among those with significant fat, using logistic regression. RESULTS: Initial biopsy specimens from most patients (88%) had no or trivial amounts of fat. Among second biopsy samples, 74% had no or trivial fat and 13% had significant amounts of fat. The strongest risk factors for progression of steatosis were alcohol abuse and overweight/obesity; cumulative exposure to antiretroviral therapy between biopsies and high counts of CD4(+) T cells were associated with reduced progression of steatosis. Among the 28 patients whose initial biopsy specimen had significant fat levels, most (75%) regressed. CONCLUSIONS: Antiretroviral therapy and high counts of CD4(+) T cells are associated with reduced progression of steatosis in patients coinfected with HIV and HCV. Efforts to diagnose and prevent steatosis should focus on persons with a high body mass index and excessive alcohol intake.
BACKGROUND & AIMS:Hepatic steatosis is a common histologic finding in patients coinfected with humanimmunodeficiency virus (HIV) and hepatitis C virus (HCV), although little is known about its natural history. We prospectively examined the natural history of steatosis in patients coinfected with HIV and HCV who attended an urban HIV clinic. METHODS: The study cohort consisted of 222 coinfected patients (87% black, 94% with HCV genotype 1 infection) who had at least 2 liver biopsies performed between 1993 and 2008. Biopsy specimens were scored by a single pathologist; samples were classified as having trivial (<5% of hepatocytes affected) or significant (>5%) levels of fat (steatosis). We characterized progression to significant levels of fat among patients whose first biopsy samples had no or trivial levels of fat, and regression among those with significant fat, using logistic regression. RESULTS: Initial biopsy specimens from most patients (88%) had no or trivial amounts of fat. Among second biopsy samples, 74% had no or trivial fat and 13% had significant amounts of fat. The strongest risk factors for progression of steatosis were alcohol abuse and overweight/obesity; cumulative exposure to antiretroviral therapy between biopsies and high counts of CD4(+) T cells were associated with reduced progression of steatosis. Among the 28 patients whose initial biopsy specimen had significant fat levels, most (75%) regressed. CONCLUSIONS: Antiretroviral therapy and high counts of CD4(+) T cells are associated with reduced progression of steatosis in patients coinfected with HIV and HCV. Efforts to diagnose and prevent steatosis should focus on persons with a high body mass index and excessive alcohol intake.
Authors: Barbara H McGovern; Jeremy S Ditelberg; Lynn E Taylor; Rajesh T Gandhi; Katerina A Christopoulos; Stacey Chapman; Beth Schwartzapfel; Emily Rindler; Anne-Marie Fiorino; M Tauheed Zaman; Paul E Sax; Fiona Graeme-Cook; Patricia L Hibberd Journal: Clin Infect Dis Date: 2006-06-22 Impact factor: 9.079
Authors: T Poynard; P Halfon; L Castera; F Charlotte; B Le Bail; M Munteanu; D Messous; V Ratziu; Y Benhamou; M Bourlière; V De Ledinghen Journal: Aliment Pharmacol Ther Date: 2007-03-15 Impact factor: 8.171
Authors: P Halfon; G Pénaranda; F Carrat; P Bedossa; M Bourlière; D Ouzan; C Renou; A Tran; E Rosenthal; C Wartelle; P Delasalle; P Cacoub Journal: Aliment Pharmacol Ther Date: 2009-03-09 Impact factor: 8.171
Authors: Mark S Sulkowski; Shruti H Mehta; Michael S Torbenson; Yvonne Higgins; Sherilyn C Brinkley; Ruben Montes de Oca; Richard D Moore; Nezam H Afdhal; David L Thomas Journal: AIDS Date: 2007-10-18 Impact factor: 4.177
Authors: Richard K Sterling; Melissa J Contos; Paula G Smith; R Todd Stravitz; Velimir A Luketic; Michael Fuchs; Mitchell L Shiffman; Arun J Sanyal Journal: Hepatology Date: 2008-04 Impact factor: 17.425
Authors: L Castéra; M A Loko; B Le Bail; P Coffie; V De Ledinghen; P Trimoulet; M Winnock; F Dabis; D Neau Journal: Aliment Pharmacol Ther Date: 2007-09-28 Impact factor: 8.171
Authors: Firouzé Bani-Sadr; Fabrice Carrat; Pierre Bedossa; Lionel Piroth; Patrice Cacoub; Christian Perronne; Claude Degott; Stanislas Pol Journal: AIDS Date: 2006-02-28 Impact factor: 4.177
Authors: Emilio González-Reimers; Javier López-Prieto; Geraldine Quintero-Platt; Ricardo Pelazas-González; M Remedios Alemán-Valls; Onán Pérez-Hernández; M José de-la-Vega-Prieto; M Angeles Gómez-Rodríguez; Candelaria Martín-González; Francisco Santolaria-Fernández Journal: World J Hepatol Date: 2016-01-08